FDA catalysts, PDUFA dates with approval probability, drug pipeline, cash runway and insider activity — updated automatically from SEC, FDA and ClinicalTrials.gov data.
OSTX holds $917,552 in cash and burns about $4.1M/quarter from operations, giving an estimated runway of 0.7 months. A recent offering filing was detected — dilution watch.
Source: SEC EDGAR XBRL (operating cash flow). Get dilution alerts for OSTX free →
| Date | Insider | Type | Value |
|---|---|---|---|
| 2026-02-13 | PETIT ROBERT |
Purchase | $0 |
| 2026-02-13 | Jarry Olivier Roger |
Purchase | $0 |
| 2026-02-13 | Galzahr Karim |
Purchase | $0 |
| 2026-02-13 | Romness Paul A. |
Purchase | $0 |
| 2026-02-13 | Acevedo Christopher P. |
Purchase | $0 |
A free BioRadar account adds AI daily briefings, sentiment tracking, trial enrollment progress, and email alerts for OSTX and 2 more tickers of your choice.
Create Free Account →